Emicizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Emicizumab and local guidelines before prescribing.
Bispecific antibody
Mechanism
Bispecific antibody mimicking factor VIII.
Uses
Prophylaxis in haemophilia A.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reaction, thrombotic microangiopathy with aPCC.
Interactions
Activated prothrombin complex concentrate with caution.
Contraindications and cautions
Hypersensitivity
Monitoring
Bleeding episodes
Pregnancy and breastfeeding
Specialist advice
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Does not need factor VIII activity monitoring; interferes with some coagulation assays.
More from the textbook: uses, cautions and other points
- Haemophilia A (factor VIII) and B (factor IX) - X-linked (mainly males; female carriers may bleed); bleeding into joints (haemarthrosis) and muscles; long APTT, normal PT; factor concentrates, emicizumab (haemophilia A), gene therapy; avoid IM injections and NSAIDs.
Haematology: Anatomy Physiology and Pharmacology - Haemophilia treatments - factor VIII or IX concentrates; emicizumab (SC antibody that mimics factor VIII - prophylaxis in haemophilia A, including those with inhibitors; caution with activated PCC - thrombotic microangiopathy); bypassing agents (recombinant factor VIIa) for inhibitors; gene therapy in specialist centres.
Haematology: Anatomy Physiology and Pharmacology - Emicizumab | Factor VIII mimic for haemophilia A prophylaxis.
Haematology: Anatomy Physiology and Pharmacology - Emicizumab - a weekly to monthly subcutaneous antibody that mimics factor VIII, used as prophylaxis in haemophilia A.
Haematology: Haemostasis and Thrombosis - Emicizumab | Subcutaneous prophylaxis in haemophilia A.
Haematology: Haemostasis and Thrombosis - Treatment - factor concentrates (prophylaxis), emicizumab (subcutaneous bispecific antibody - haemophilia A), gene therapy (approved for selected adults with haemophilia A and B); avoid IM injections and NSAIDs; inhibitor development is a key complication.
Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders - Inhibitors (antibodies against the factor) - bypassing agents (recombinant factor VIIa, FEIBA) or emicizumab.
Haematology: Haemostasis and Thrombosis - Haemophilia A / B | F8 / F9 - XLR | Haemarthrosis, prolonged APTT; factor, emicizumab, gene therapy
Clinical Genetics: Single-gene, repeat-expansion and mitochondrial disorders